Assessment of mazindane, a pro-drug form of mazindol, in assays used to define cocaine treatment agents

European Journal of Pharmacology

Volumn 458, Issue 3, 2003, Pages 263-273

  Houlihan, William J ^a   Kelly, Lawrence ^a  

^a DREW UNIVERSITY   (United States)

Author keywords

(Mouse); (Rat); (Rhesus monkey); Cocaine discrimination; Mazindane; Mazindol; Motor activity; Mouse; Neurotransmitter binding

Indexed keywords

3BETA (4 FLUOROPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; COCAINE; HISTAMINE H1 RECEPTOR; ISOINDOLE DERIVATIVE; MAZINDANE; MAZINDOL; MUSCARINIC M1 RECEPTOR; PROADIFEN; SEROTONIN 1A RECEPTOR; SEROTONIN 3 RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; ASSAY; CONTROLLED STUDY; DISCRIMINATIVE STIMULUS; DOSE RESPONSE; DRUG ACTIVITY; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; DRUG SOLUBILITY; LIGAND BINDING; LOCOMOTION; MALE; MOTOR ACTIVITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT STRAIN; RHESUS MONKEY;

ANALYSIS OF VARIANCE; ANIMALS; BINDING, COMPETITIVE; CELL MEMBRANE; COCAINE; DISCRIMINATION (PSYCHOLOGY); DISCRIMINATION LEARNING; DOPAMINE UPTAKE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; MACACA MULATTA; MALE; MAZINDOL; MICE; MOTOR ACTIVITY; NEUROTRANSMITTER AGENTS; PROADIFEN; RATS; RATS, SPRAGUE-DAWLEY; TRITIUM;

EID: 0037419531     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(02)02791-7     Document Type: Article

References (36)

1. Aeberli P., Eden P., Gogerty J.H., Houlihan W.J., Penberthy C. 5-Aryl-2, 3-dihydro-5H-imidazo [2, 1-a] isoindols. A novel class of anorectic agents. J. Med. Chem. 18:1975;177-181.
2. Alvarez B., Dahlitz M., Grimshaw J., Parkes J.D. Mazindol in long-term treatment of narcolepsy. Lancet. 337:1991;1293-1294.
3. Berger P., Gawin F., Kosten T.R. Treatment of cocaine abuse with mazindol. Lancet. 2:1984;283.
4. Bray G.A. A concise review on the therapeutics of obesity. Nutrition. 16:2000;953-960.
5. Chait L.D., Uhlenhuth E.H., Johanson C.E. The discriminative stimulus and subjective effects of phenylpropanolamine, mazindol and D-amphetamine in humans. Pharmacol. Biochem. Behav. 24:1986;1667-1672.
6. Chait L.D., Uhlenhuth E.H., Johanson C.E. Reinforcing and subjective effects of several anorectics in normal human volunteers. J. Pharmacol. Exp. Ther. 242:1987;777-783.
7. Coakley J.H., Moorcraft J., Hipkin L.J., Smith C.S., Griffiths R.D., Edwards R.H. The effect of mazindol on growth hormone secretion in boys with Duchenne muscular dystrophy. J. Neurol. Neurosurg. Psychiatry. 51:1988;1551-1557.
8. Corwin R.L., Woolverton W.L., Schuster C.R., Johanson C.E. Anorectics: effects on food intake and self-administration in rhesus monkeys. Alcohol Drug Res. 7:1987;351-361.
9. de Felice E.A., Chaykin L.B., Cohen A. Double-blind clinical evaluation of mazindol, dextroamphetamine, and placebo in treatment of exogenous obesity. Curr. Ther. Res. 15:1973;358-366.
10. Engstrom R.G., Kelly L.A., Gogerty J.H. The effects of 5-hydroxy-5-(4′-chlorphenyl)-2, 3-dihydro-5H-imidazo (2, 1-a) isoindole (mazindol, SaH 42-548) on the metabolism of brain norepinephrine. Arch. Int. Pharmacodyn. Ther. 244:1975;308-321.
11. Gogerty J.H., Penberthy C., Iorio L.C., Trapold J.H. Pharmacological analysis of a new anorexic substance: 5-hydroxy-5-(4′-chlorophenyl)-2, 3-dihydro-5H-imidazo [2, 1-a] isoindole (mazindol). Arch. Int. Pharmacodyn. Ther. 214:1975;285-307.
12. Götestam K.G., Gunne L.M. Subjective effects of two anorexigenic agents fenfluramine and AN-448 in amphetamine-dependent subjects. Br. J. Addict. 67:1972;39-44.
13. Griggs R.C., Moxley R.T., Medell J.R., Fenichel G.M., Brooke M.H., Miller P.J., Mandel S., Florence J., Schierbecker J., Kaiser K.K. Randomized double-blind trial of mazindol in Duchenne dystrophy. Muscle Nerve. 13:1990;1169-1173.
14. Heikkila R.E., Babington R.G., Houlihan W.J. Pharmacological studies with several analogs of mazindol: correlation between effects on dopamine uptake and various responses. Eur. J. Pharmacol. 71:1981;277-286.
15. Houlihan W.J., Boja J.W., Parrino V.A., Kopajtic T.A., Kuhar M.J. Halogenated mazindol analogs as potential inhibitors of the cocaine binding site at the dopamine transporter. J. Med. Chem. 39:1996;4935-4941.
16. Houlihan W.J., Boja J.W., Kopajtic T.A., Kuhar M.J., Degrado S.J., Toledo L. Positional isomers and analogs of mazindol as potential inhibitors of the cocaine binding site on the dopamine transporter. Med. Chem. Res. 8:1998;77-90.
17. Houlihan W.J., Kelly L., Pankuch J., Koletar J., Brand L., Janowsky A., Kopajtic T.A. Mazindol analogs as potential inhibitors of the cocaine binding site at the dopamine transporter. J. Med. Chem. 45:2002;4097-4109.
18. Houlihan W.J., Ahmad U.F., Koletar J., Brand L., Kopajtic T.A. Benzo- and cyclohexano mazindol analogs as potential inhibitors of the cocaine binding site at the dopamine transporter. J. Med. Chem. 45:2002;4110-4118.
19. Inoue S. Clinical Studies with mazindol. Obes. Res. 3:1998;549S-552S.
20. 3H] Mazindol binding associates with neural dopamine and norepinephrine uptake sites. Mol. Pharmacol. 26:1984;35-44.
21. Kleven M.S., Anthony E.W., Woolverton W.L. Pharmacological characterization of the discriminative effects of cocaine in rhesus monkeys. J. Pharmacol. Exp. Ther. 254:1990;312-317.
22. Kulkarni S.S., Newman A.H., Houlihan W.J. Three dimensional quantitative structure activity relationships of mazindol analogues at the dopamine transporter. J. Med. Chem. 45:2002;412-4119.
23. Mansbach R.S., Balster R.L. Effects of mazindol on behavior maintained or occasioned by cocaine. Drug Alcohol Depend. 31:1993;183-191.
24. Margolin A., Avants S.K., Kosten T.R. Mazindol for relapse prevention to cocaine abuse in methadone-maintained patients. Am. J. Drug Alcohol Abuse. 21:1995;469-481.
25. Margolin A., Avants S.K., Malison R.T., Kosten T.R. High and low-dose mazindol for cocaine dependence in methadone-maintained patients: a preliminary evaluation. Subst. Abuse. 18:1997;125-131.
26. Metlesics, W., Sternbach, L.H., 1977. U.S. Patent 4,018,765.
27. Netter K.J. Inhibition of oxidative metabolism in microsomes. Pharmacol. Ther. 10:1980;515-535.
28. Parkes J.D., Schacter M. Mazindol in the treatment of narcolepsy. Acta Neurol. Scand. 60:1979;250-254.
29. Preston K.L., Sullivan J.T., Berger P., Bigelow G.E. Effects of cocaine alone and in combination with mazindol in human cocaine abusers. J. Pharmacol. Exp. Ther. 267:1993;296-307.
30. Ritz M.C., Lamb R.J., Goldberg S.R., Kuhar M.J. Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science. 237:1987;1219-1223.
31. Seibyl, J.P., Krysal, J.H., Charney, D.S., 1993. WO 93/21917.
32. Shriver, D.A., Gluckman, M.L., 1976. US Patent 3,966,955.
33. Stine S.M., Krystal J.H., Kosten T.R., Charney D.S. Mazindol treatment for cocaine dependence. Drug Alcohol Depend. 39:1995;245-252.
34. Vespignani H., Barroche G., Escaillis J.P., Weber M. Importance of mazindol in the treatment of narcolepsy. Sleep. 7:1979;274-275.
35. Witkin J.M., Nichols D.E., Katz J.L. Behavioral effects of selective dopaminergic compound in rats discriminating cocaine injections. J. Pharmacol. Exp. Ther. 255:1991;706-713.
36. Woodhouse, C.R.J., 1983. US Patent 4,416,894.